000			03479nam a22003375i 4500
001			76010
003			ES-MaUEC
005			20230202101840.0
007			cr nn 008mamaa
008			130707s2013 xxu| s |||| 0|eng d
020			_a9781461479406
024	7		_a10.1007/978-1-4614-7940-6 _2doi
050		4	_aRM666.C266 _bE53 2013 EB
082	0	4	_a612.8
245	0	0	_aEndocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders _cedited by Elisabeth J. Van Bockstaele
260			_aNew York _bSpringer International Publishing _c2013
300			_a1 recurso en línea (IX, 337 p.) _b26 ilustraciones, 7 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aEndocannabinoids and monoamines: modulating the modulators -- Endocannabinoid-mediated synaptic plasticity -- Current cannabinoid receptor nomenclature and pharmacological principles -- Cue-elicited craving for cannabis activates the reward neurocircuitry associated with the neuropathology of addiction -- Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders -- Pathophysiology of mood disorders and mechanisms of action of antidepressants and mood stabilizers -- Anatomical, biochemical and behavioral evidence for cannabinoid modulation of noradrenergic circuits: role of norepinephrine in cannabinoid-induced aversion -- Gender Disparity of Depression: The Role of Endocannabinoids and Noradrenergic Function -- Endocannabinoids, Monoamines and Stress -- Chronic effects of cannabinoid drugs on monoaminergic systems and the role of endocannabinoids and cannabinoid receptors in human brain disorders -- Endocannabinoid Signaling and the Regulation of the Serotonin System -- Modulation of serotonin firing activity through CB1 agonists and FAAH inhibitors -- Involvement of serotonergic system in cannabinoid analgesia -- Cannabinoids, monoamines, COMT and schizophrenia: pathobiological mechanisms in psychosis
520			_aThe past decade has seen tremendous growth in the study of cannabinoid receptor signaling in brain. The impact and consequences of cannabinoid modulation of monoaminergic (dopamine, norepinephrine, and serotonin) circuits is becoming more clear. Scientists have shown significant interaction between these two systems in a variety of psychiatric and neurological disorders such as affective disorders, multiple sclerosis, and pain or pain disorders. The overarching goal of Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders is to provide current information on advances in the field of endocannabinoid signaling and potential therapeutic applications with a particular emphasis on monoaminergic circuits
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGERrevisado
650		7	_aCannabis _xUso terapéutico _9262120 _0comprobar BNE19983251539 _2embne
700	1		_aVan Bockstaele, Elisabeth J. _eeditor _984807 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-7940-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12816280 _b10-10-17 _c01-10-14
998			_am _a_alco _a_vill _b04-04-17 _cm _dz _eu _feng _gxxu _h0
945			_aRM666.C266 E53 2013 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11545665 _z06-04-17
999			_c76010 _d76010 _x1